Amini: The systemic landscape is constantly changing and is very exciting. It will only become more complicated for our ...
Amini: This varies quite a bit by stage — operable vs. nonoperable — and patients’ performance status and preference. Additionally, more relevant to medical oncology but equally, if not more, ...
March 20 (Reuters) - The U.S. Food and Drug Administration on Friday approved Bristol Myers Squibb's combination treatment ...
In the U.S., FDA approval establishes Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) as the first immunotherapy combination approved for adult and pediatric patients 12 ...
Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses in ...
Pfizer announces phase 3 TALAPRO-3 study of talzenna plus Xtandi significantly improves rPFS in metastatic prostate cancer: New York Friday, March 20, 2026, 09:00 Hrs [IST] Pfizer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results